Fresenius Medical Care AGFMS -0.04%72 Buyback Yield % is 3.17 as of Jun. 27, 2026, which is 73% above its 10-year median of 1.83. GuruFocus rates FMS with a GF Score™ of 72/100 and a GF Value™ of $23.50 (Fairly Valued). The stock has 4 warning signs investors should review. Among 271 Healthcare Providers & Services companies, Fresenius Medical Care AG ranks better than 84.87% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Fresenius Medical Care AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius Medical Care AG Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Fresenius Medical Care AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius Medical Care AG (FMS) has a Buyback Yield % of 3.17 as of Jun. 27, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Fresenius Medical Care AG and its competitors. This is 73% above median its historical median of 1.83. Over the past decade, Fresenius Medical Care AG's Buyback Yield % has ranged from 0.14 to 5.14. According to the industry distribution chart, Fresenius Medical Care AG ranks #41 out of 271 companies in the Healthcare Providers & Services industry, placing it in the top 15.1%.
Is Fresenius Medical Care AG's Buyback Yield % too high?
Fresenius Medical Care AG's current Buyback Yield % of 3.17 is 73% above median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 5.14. Based on the distribution chart, Fresenius Medical Care AG ranks #41 out of 271 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Fresenius Medical Care AG has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius Medical Care AG's Buyback Yield % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius Medical Care AG ranks #41 out of 271 companies for Buyback Yield %. This places Fresenius Medical Care AG in the top 15% of its industry — outperforming the majority of peers. Historically, Fresenius Medical Care AG's own Buyback Yield % has ranged from 0.14 to 5.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Fresenius Medical Care AG and its competitors. Fresenius Medical Care AG's current Buyback Yield % is 3.17, which is 73% above median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius Medical Care AG stock overvalued right now?
Based on GuruFocus' analysis, Fresenius Medical Care AG (FMS) is currently considered Fairly Valued. The stock's GF Value™ is $23.50, compared to a current price of $23.24 — trading 1.1% below its estimated fair value. The current Buyback Yield % is 3.17, which is 73% above median its 10-year median of 1.83. Fresenius Medical Care AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Fresenius Medical Care AG (FMS), the current Buyback Yield % is 3.17 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius Medical Care AG (FMS) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius Medical Care AG stock appears to be undervalued.
The current stock price of $23.24 is trading 1.1% below its estimated GF Value™ of $23.50.
GuruFocus considers Fresenius Medical Care AG to be Fairly Valued.
Key valuation signals for FMS:
Buyback Yield %: 3.17 (73% above median its 10-year median of 1.83)
GF Value™: $23.50 vs. price of $23.24 (1.1% below fair value)
No single metric tells the full story. See the FMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
72GF Score
Get the complete analysis for FMS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FMS has been successfully added to your 
